Benjamin Tomlinson
Clinical trials sponsored by Benjamin Tomlinson, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Low-Dose cocktail aims to outsmart MDS resistance Results expected Nov 2026 (estimated)
- New gentle chemo combo after transplant aims to stop leukemia relapse Results expected Dec 2026 (estimated)
-
New Low-Dose cocktail aims to outsmart MDS resistance
Disease control Recruiting nowThis early study tests a new way of giving two FDA-approved drugs (5-azacitidine and decitabine) for myelodysplastic syndromes (MDS), a type of bone marrow failure. Instead of standard doses, the drugs are given at low doses on alternating weeks to try to overcome resistance. Abo…
Early phase 1 • Sponsor: Benjamin Tomlinson • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New gentle chemo combo after transplant aims to stop leukemia relapse
Disease control Recruiting nowThis study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up t…
Phase 1/2 • Sponsor: Benjamin Tomlinson • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC